Integrilin (eptifibatide) / Takeda - LARVOL DELTA

Therapeutic Plasma Exchange for Uncontrollable Bleeding After Platelet Inhibition with Ticagrelor: A Report of 2 Cases. (PubMed, Am J Case Rep) - "He underwent emergency percutaneous coronary intervention and was started on dual antiplatelet therapy (aspirin 81 mg/day, and ticagrelor 90 mg twice daily)...Our second case was a 66-year-old man who received single doses of ticagrelor (180 mg) and eptifibatide (180 mcg/kg) during an attempted PCI...Platelet reactivity increased immediately following the procedure; bleeding was stabilized, and no further blood products were required after postoperative day 1. CONCLUSIONS TPE may be an effective novel option for emergency removal of circulating ticagrelor in refractory bleeding cases."

Journal • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Myocardial Infarction

Radiographic Bleeding Risk After Carotid Stenting for Stroke: Eptifibatide and a Predictive Score (SCCM 2026) - "Eptifibatide was associated with increased radiographic but not symptomatic ICH. This bleeding risk appeared linked to higher stroke severity and more urgent intervention in the eptifibatide+DAPT group. A risk score may help guide individualized antiplatelet decisions during emergent carotid stenting."

Cardiovascular • Cerebral Hemorrhage • Diabetes • Hematological Disorders • Ischemic stroke • Metabolic Disorders

Comparative Study of Hemorrhagic Conversion After Treatment With Eptifibatide vs Oral DAPT (SCCM 2026) - "Eptifibatide was not observed to increase rates of adverse outcomes compared to PO DAPT post-thrombolytics and MT in patients with AIS. Further research is needed to determine the impact of eptifibatide utilization in known, asymptomatic hemorrhagic conversion patients post-thrombolytics and MT."

Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Ischemic stroke

Evaluation of the real-world safety of eptifibatide in the treatment of ARDS: results of a disproportionality analysis of FAERS data. (PubMed, Front Med (Lausanne)) - "The study also highlighted the importance of early detection of adverse reactions to Eptifibatide. This research provides insights into both known and potential adverse reactions associated with Eptifibatide in real-world clinical use, offering additional safety information for clinicians when prescribing Eptifibatide for ARDS treatment."

Journal • Real-world evidence • Acute Coronary Syndrome • Acute Respiratory Distress Syndrome • Allergy • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Hypotension • Myocardial Infarction • Pancreatitis • Pulmonary Disease • Respiratory Diseases • Septic Shock • Thrombocytopenia

ACUTE STEMI FROM CORONARY EMBOLISM IN A YOUNG MALE WITH POLYCYTHEMIA VERA (ACC 2026) - "He was started on aspirin, ticagrelor, statin, and ezetimibe; eptifibatide was stopped due to bleeding...Due to recurrent arterial events, apixaban was started, aspirin stopped, ticagrelor continued. Heart failure therapy and hydroxyurea were continued... PV can cause embolic STEMI without coronary disease. Early recognition and tailored therapy led to stable recovery."

Cardiovascular • Chronic Eosinophilic Leukemia • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Hematological Disorders • Hypertension • Myocardial Infarction • Polycythemia Vera • Thrombosis • JAK2

ACUTE LEFT MAIN THROMBOTIC OCCLUSION IN A YOUNG PATIENT WITH DIFFUSE CORONARY ECTASIA (ACC 2026) - "Cangrelor was transitioned to eptifibatide and heparin before discharge on DAPT. Acute LM thrombosis in diffuse ectasia is complex. Balloon angioplasty with adjunctive pharmacologic and mechanical support can stabilize patients when stenting is not feasible. Individualized management is critical in this rare but lethal scenario."

Clinical • Atherosclerosis • Cardiovascular • CNS Disorders • Depression • Gout • Hematological Disorders • Hypertension • Inflammatory Arthritis • Thrombosis

EFFICACY AND SAFETY OF ADJUNCTIVE INTRACORONARY GLYCOPROTEIN IIB/IIIA INHIBITORS COMBINED WITH ASPIRATION THROMBECTOMY VERSUS ASPIRATION THROMBECTOMY ALONE IN STEMI PATIENTS UNDERGOING PRIMARY PCI: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (ACC 2026) - "Combination therapy significantly improved TMPG (RR:1.12, 95%CI:1.02-1.23, P=0.02), driven by tirofiban (RR:1.12, 95%CI:1.01-1.23, P=0.03). TIMI 3 flow showed overall non-significant improvement (RR:1.10, 95%CI:0.99-1.21, P=0.06), but improved with eptifibatide use (RR:1.31, 95%CI:1.01-1.71, P=0.04)... Adjunctive intracoronary GPI with AT improves microvascular perfusion markers without increasing bleeding risk in STEMI patients undergoing PPCI, with effects varying by GPI agents."

Retrospective data • Cardiovascular • Myocardial Infarction • Thrombosis

PRIMARY PCI: A CASE OF DEFERRED STENTING GUIDED BY INTRAVASCULAR IMAGING (ACC 2026) - "After 4.5×15mm balloon inflation,TIMI 3 flow, residual mid-RCA lesion& distal thrombus embolisation.Thus,stenting deferred; eptifibatide infusion, enoxaparin given.7 days later,TIMI 3 flow in RCA. In HTB with no-reflow,OCT-guided deferred stenting in TIMI 3 flow with adequate MLA may be an alternative to PPCI stenting in large arteries."

Clinical • Thrombosis

A CLOT OUT OF NOWHERE: UNMASKING ANTIPHOSPHOLIPID SYNDROME IN A STEMI PATIENT (ACC 2026) - "An intra-aortic balloon pump (IABP) was placed, and the patient was initiated on dual antiplatelet therapy, including eptifibatide and heparin...Distinguishing embolic from thrombotic STEMI guided transition from apixaban to warfarin with heparin bridging, as APS has a higher recurrence on direct oral anticoagulants. This case illustrates the importance of distinguishing embolic from thrombotic STEMI, particularly in autoimmune patients. Careful chart review, recognition of APS, and appropriate anticoagulant selection were crucial in altering long-term management with indefinite warfarin to reduce recurrence risk."

Clinical • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease • Genetic Disorders • Hematological Disorders • Hypertension • Immunology • Myocardial Infarction • Myositis • Scleroderma • Systemic Sclerosis • Thrombosis

TOO BIG TO STENT: OMI IN A SEVERELY ECTATIC RCA (ACC 2026) - "In this young patient with OMI and severely ectatic coronary vasculature precluding PCI, aspiration thrombectomy followed by eptifibatide infusion achieved vessel recanalization."

Cardiovascular • Hypertension • Myocardial Infarction • Thrombosis

Safety and Feasibility of Same-Admission Transcarotid Arterial Revascularization Prior to Heart Surgery for Patients Presenting With Concurrent, Severe Carotid Artery Stenosis, and Surgical Cardiac Disease. (PubMed, HCA Healthc J Med) - "Bridging anticoagulation treatment included aspirin and either heparin infusion (60.0%, n = 9), intravenous antiplatelet therapy such as cangrelor or eptifibatide (33.33%, n = 5), or subcutaneous enoxaparin (6.67%, n = 1). In our experience, a range of anticoagulation bridging therapies did not result in apparent stent thrombosis and can be employed until the cardiac surgeon deems it safe to initiate oral dual antiplatelet therapy. Further studies with larger datasets are required to support the broader adoption of TCAR prior to heart surgery in patients with concurrent, severe cardiac and carotid disease."

Journal • Anesthesia • Cardiovascular • Coronary Artery Disease • Heart Failure • Hematological Disorders • Myocardial Infarction • Thrombosis

Spontaneous Proximal Middle Cerebral Artery Dissection due to Stimulant-associated Vascular Injury (AAN 2026) - "Given the severity of her deficits, she received IV Tenecteplase and was transferred for thrombectomy...She was treated with IV eptifibatide and transitioned to aspirin 81 mg daily...Given her use of bupropion and Adderall, stimulant-associated vascular injury was considered... Intracranial arterial dissection (IAD) is a rare cause of stroke in the young that frequently requires angiography for diagnosis. Management remains unstandardized and necessitates broad differential consideration for underlying etiology. In our unique case, a potential cause may have been stimulant-associated vascular injury, as amphetamine derivatives have been linked to vasculopathy, vasospasm, and vessel wall injury."

ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Cardiovascular • CNS Disorders • General Anxiety Disorder • Giant Cell Arteritis • Hematological Malignancies • Immunology • Ischemic stroke • Thrombosis

A Monoclonal Antibody to Platelet αIIbβ3 That Inhibits Protein Disulfide Isomerase Binding and Platelet Aggregation. (PubMed, Blood Adv) - "R21C11 bound slowly to unactivated platelets and more rapidly after T6 activation; eptifibatide, which induces the αIIbβ3 extended-open conformation, also increased the speed of R21C11 binding...These data are consistent with R21C11 inhibiting PDI binding by steric hindrance and the activation-dependence of PDI binding. Taken together, these data suggest that the β-tail domain and/or neighboring area is the binding site for PDI on integrin αIIbβ3."

Journal • Cardiovascular • Hematological Disorders • Thrombosis

Glycoprotein IIb/IIIa Agents in Acute Ischemic Stroke: A Niche in the Making? (PubMed, Stroke) - "Emerging treatments, designed to target distinct components of the thrombus, are currently under evaluation and offer renewed hope for enhancing clot dissolution and improving clinical outcomes. This review will examine the current evidence surrounding glycoprotein IIb/IIIa inhibitors in the treatment of acute ischemic stroke, drawing on the latest randomised-controlled trials, identifying promising therapeutic candidates and evaluating the clinical contexts in which these agents are most likely to be beneficial."

Journal • Review • Cardiovascular • Ischemic stroke • Thrombosis

Galectin-3 binds to the RGD-binding site in a glycan-independent manner and to the allosteric site and activates integrins αvβ3, αIIbβ3, and α5β1. (PubMed, bioRxiv) - "RGDfV or eptifibatide inhibited Gal3 binding to αvβ3 and αIIbβ3, respectively, but lactose, pan-galectin inhibitor, did not inhibit Gal3 binding to integrins...Known anti-inflammatory agents, Ivermectin, NRG1, and FGF1 inhibited integrin activation induced by Gal3 in αvβ3 and αIIbβ3. These findings suggest that Gal3 binding to site 2 may be a potential mechanism of pro-inflammatory and pro-thrombotic action of Gal3."

Journal • Oncology • IL6 • LGALS3 • NRG1

Decreased Silent Brain Ischemic Lesions Following Aneurysm Flow Diversion with Intraoperative Eptifibatide: A Retrospective Study and a Meta-Analysis (ISC 2026) - "Higher (> mean) fluoroscopy time (OR 15.42, 95% CI 2.64–90.00, p = 0.002), higher (> mean) fluoroscopy dose (OR 6.88, 95% CI 1.35–34.97, p = 0.020), and ASA/Plavix DAPT regimen (OR 9.33, 95% CI 1.05–82.78, p = 0.045) were significantly associated with DWI lesion occurrence. The overall pooled incidence of DWI lesions was 56% (95% CI: 32%–77%). The rate of DWI lesions in our cohort was significantly lower than in the pooled cohort (OR = 0.11, 95% CI = [0.043–0.24], p < 0.001) and seven of the eight individual cohorts (all p≤0.002).ConclusionsIntraoperative eptifibatide may decrease the incidence of DWI lesions during flow diversion procedures without increasing the risk for hemorrhagic complications."

Retrospective data • Cardiovascular • Hematological Disorders • Vascular Neurology

Stroke Phenotypes and Treatment Response: A Latent Class Analysis of an Acute Stroke Trial (ISC 2026) - "INTRODUCTION: The Multi-Arm Optimization of Stroke Thrombolysis (MOST) trial found no benefit of adjunctive argatroban or eptifibatide with intravenous thrombolytic therapy for acute ischemic stroke and reported significantly greater post-stroke disability and higher mortality in the argatroban group. Adjustment for stroke phenotypes attenuated the relationship between argatroban and functional outcomes, eliminating statistical significance. However, stroke profiles did not account for the excess mortality observed in the argatroban arm. These findings suggest that stratified stroke phenotypes may help explain observed differences in functional recovery but are insufficient to explain mortality risk."

Cardiovascular • Ischemic stroke

Observations from Hotline Usage in an Acute Stroke Trial: Characteristics of Complex Cases (ISC 2026) - "Background The Multi-arm Optimization of Stroke Thrombolysis (MOST) trial was a single-blind, phase 3, randomized trial evaluating whether adjunctive treatment with argatroban or eptifibatide alongside IV thrombolysis improved outcomes. Higher sICH and mortality in the hotline group likely reflect the greater complexity of cases for which support was sought. These findings highlight the value of 24/7 expert support in acute care trials to guide decision-making and uphold protocol integrity under pressure."

Clinical • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders

Two Decades of Real-World Data Reveals: Vigilance Signals of Drug-Induced Gingival Bleeding. (PubMed, Int Dent J) - "This study profiles drug-induced GB and identifies potential culprit drugs, which aids in understanding drug safety and optimising clinical practice."

Journal • Real-world evidence • Dental Disorders • Infectious Disease • Oncology • Periodontitis

E-TWIST: Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis (clinicaltrials.gov) - P3 | N=786 | Not yet recruiting | Sponsor: Xinqiao Hospital of Chongqing

New P3 trial • Cardiovascular • Ischemic stroke

Safety and efficacy of adjunctive Tirofiban and Eptifibatide in acute ischemic stroke: a systematic review and meta-analysis. (PubMed, J Stroke Cerebrovasc Dis) - "Our meta-analysis suggests that while adjunctive tirofiban or eptifibatide with IVT do not yield benefits in terms of reducing mortality or improving functional independence at 90 days in AIS, emerging evidence from RCTs indicates that tirofiban may offer functional benefits, though this remains uncertain. Importantly, adjunctive therapy did not demonstrate a significant increase in bleeding risk in the analyzed studies. . These findings support the need for further large-scale, high-quality randomized controlled trials to explain the role of tirofiban in the management of AIS."

Journal • Retrospective data • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke • Vascular Neurology

Eptifibatide Use in Mechanical Thrombectomy for Acute Ischemic Stroke (ASHP 2025) - No abstract available

Cardiovascular • Ischemic stroke

Intravenous Antiplatelets in Transition: Evaluating Eptifibatide and Cangrelor for Neurointerventional Radiology and Perioperative Bridging (ASHP 2025) - No abstract available

A murine monoclonal antibody to integrin αIIbβ3 that inhibits protein disulfide isomerase binding to platelets and platelet aggregation (ASH 2025) - "Eptifibatide, which induces αIIbβ3 to adopt the extended-open conformation, alsoincreased the speed and amount of 21C11 bound to platelets... mAb R21C11 binding to platelet αIIbβ3: 1. Inhibits exogenous PDI binding to platelets. 2."

Preclinical • Cardiovascular • Hematological Disorders • Thrombosis

Efficacy and safety of adjunctive eptifibatide or argatroban versus control for acute ischemic stroke: A systematic review and network meta-analysis of randomized control trials (ASH 2025) - "Introduction: Acute ischemic stroke is a major cause of disability and mortality, with treatment mainlylimited to intravenous alteplase thrombolysis. Functional Independence (mRS 0-1): Eptifibatide showed superior odds versus control (OR 1.12 [0.65-1.95]) and Argatroban (OR 1.82 [0.61-5.45]), with wide confidence intervals. Argatroban versus controlyielded OR 1.05 [0.59-1.86], indicating uncertainty. Bayesian analysis showed minimal effect for Controlversus Argatroban = -0.046 [-0.65, 0.59], and slight advantage for Control versus Eptifibatide = 0.205 [-0.37, 0.78], with uncertainty."

Retrospective data • Review • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke